Same thought process went through my mind; there's a likelihood you're right. They've said they're looking for a partner with Anti-Pd-1 approvals and now they seem to have finalized their 2B plans for melanoma which might then lead one to think that they've found this partner they were looking for.?..We'll just have to wait and find out.
It could very well be that we're licensing the anti-pd-1s, though i find this an improbable scenario; given the enormous value Immunopulse presents to Anti-Pd-1 Big pharma (due to immunogenic conversion) I'd think that they'd be jumping all over it.
Let's just say that if in a few months we announce a partnership, I won't be in the least surprised.
Regardless of the way we proceed with the addition of these checkpoint inhibitors, our value will increase dramatically.
News 
Market Data 
Discover 
AI
